John Schrader, MD
Cardiovascular Disease · Enid, OKNPI 1710105077
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,926 of the $7,075 with a category attached, or 83.8%. 34 manufacturers reported payments, led by Medtronic at 32.2% of the total. Reporting peaked in 2024 at $2,123 and has fallen 70.1% since, to $635 in 2025.
Across 265 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Merck$717
- Abbott$716
- Novartis$419
- E.r. Squibb & Sons, L.L.C.$402
- Johnson & Johnson$391
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,14916%
- Food & beverage$5,92684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 24 | $2,279 |
| Merck | 42 | $717 |
| Abbott | 35 | $716 |
| Novartis | 22 | $419 |
| E.r. Squibb & Sons, L.L.C. | 19 | $402 |
| Johnson & Johnson | 26 | $391 |
| Amgen | 15 | $281 |
| Boehringer Ingelheim | 16 | $261 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $205 |
| Cvrx, Inc. | 4 | $194 |
| Impulse Dynamics (USA) Inc. | 1 | $125 |
| AstraZeneca | 7 | $123 |
| Heartflow, Inc. | 1 | $119 |
| Amarin Pharma, Inc. | 7 | $96 |
| Philips North America LLC | 1 | $68 |
| Pfizer | 4 | $68 |
| Kestra Medical Technology Services, Inc. | 2 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| Baxter Healthcare | 1 | $58 |
| Boston Scientific | 1 | $52 |
| Novo Nordisk | 3 | $42 |
| Atricure, Inc. | 2 | $41 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Edwards Lifesciences | 1 | $36 |
| Tactile Systems Technology Inc | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
| Kerecis Limited | 1 | $25 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Endologix LLC | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Cardinal Health 200 LLC | 1 | $11 |
| Aegerion Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azure$209
- SelectSecure$169
- OPTIMIZER SMART SYSTEM$125
- Reveal LINQ$108
- Barostim Neo System$103
- Confirm Rx$101
How this compares
$7,075 in reported general payments places this provider in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 817 | $727,936 |
| EntrestoSacubitril/Valsartan | 378 | $320,123 |
| XareltoRivaroxaban | 283 | $270,756 |
| Repatha SureclickEvolocumab | 263 | $194,308 |
| FarxigaDapagliflozin Propanediol | 78 | $62,361 |
| JardianceEmpagliflozin | 70 | $60,412 |
| Praluent PenAlirocumab | 66 | $32,901 |
| Dofetilide | 106 | $21,978 |
| Rosuvastatin Calcium | 1,074 | $21,545 |
| Atorvastatin Calcium | 906 | $15,876 |
| ClopidogrelClopidogrel Bisulfate | 821 | $11,625 |
| Eplerenone | 160 | $11,424 |
| Ezetimibe | 359 | $11,227 |
| Metoprolol Succinate | 700 | $11,179 |
| Carvedilol | 875 | $10,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $727,936817 claims |
| NovartisEntresto | $419 | $320,123378 claims |
| Johnson & JohnsonXarelto | $391 | $270,756283 claims |
| AstraZenecaFarxiga | $123 | $62,36178 claims |
| Boehringer IngelheimJardiance | $261 | $60,41270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Enid
- John BartolozziEnid$5K
- Nikunjkumar PatelEnid$5K
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.